Kris Cameron Wood

Wood

Associate Professor of Pharmacology and Cancer Biology

Our laboratory uses genomic and pharmacological approaches to understand how tumor dependencies are shaped by cell intrinsic factors, environmental factors, and drug treatments during the dynamic process of tumor evolution. To learn more, please visit our laboratory website: https://sites.duke.edu/woodlab/.

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Associate Professor of Cell Biology
  • Core Faculty in Innovation & Entrepreneurship
  • Member of the Duke Cancer Institute

Contact Information

  • Office Location:
  • Office Phone:
  • Email Address: kris.wood@duke.edu
  • Websites:

Education

  • Ph.D. Massachusetts Institute of Technology, 2007
  • B.S. University of Kentucky, 2002

Awards, Honors, and Distinctions

    Courses Taught

    • CMB 710B: Cell & Molecular Biology Module II
    • CMB 710E: Cell & Molecular Biology Module V
    • MOLCAN 818: Molecular Mechanisms of Oncogenesis
    • PHARM 393: Research Independent Study
    • PHARM 394: Research Independent Study
    • PHARM 493: Research Independent Study
    • PHARM 494: Research Independent Study
    • PHARM 495: Research Independent Study
    • PHARM 818: Molecular Mechanisms of Oncogenesis
    • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I

    In the News

    Representative Publications

    • Goodwin, CM; Waters, AM; Klomp, JE; Javaid, S; Bryant, KL; Stalnecker, CA; Drizyte-Miller, K; Papke, B; Yang, R; Amparo, AM; Ozkan-Dagliyan, I; Baldelli, E; Calvert, V; Pierobon, M; Sorrentino, JA; Beelen, AP; Bublitz, N; Lüthen, M; Wood, KC; Petricoin, EF; Sers, C; McRee, AJ; Cox, AD; Der, CJ, Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer., Cancer Res, vol 83 no. 1 (2023), pp. 141-157 [10.1158/0008-5472.CAN-22-0391] [abs].
    • Wood, KC; Gutkind, JS, Challenges and Emerging Opportunities for Targeting mTOR in Cancer., Cancer Research, vol 82 no. 21 (2022), pp. 3884-3887 [10.1158/0008-5472.can-22-0602] [abs].
    • Lidsky, ME; Wang, Z; Lu, M; Liu, A; Hsu, SD; McCall, SJ; Sheng, Z; Granek, JA; Owzar, K; Anderson, KS; Wood, KC, Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies., Npj Precis Oncol, vol 6 no. 1 (2022) [10.1038/s41698-022-00320-5] [abs].
    • Kishton, RJ; Patel, SJ; Decker, AE; Vodnala, SK; Cam, M; Yamamoto, TN; Patel, Y; Sukumar, M; Yu, Z; Ji, M; Henning, AN; Gurusamy, D; Palmer, DC; Stefanescu, RA; Girvin, AT; Lo, W; Pasetto, A; Malekzadeh, P; Deniger, DC; Wood, KC; Sanjana, NE; Restifo, NP, Cancer genes disfavoring T cell immunity identified via integrated systems approach., Cell Reports, vol 40 no. 5 (2022) [10.1016/j.celrep.2022.111153] [abs].
    • Lin, KH; Rutter, JC; Xie, A; Killarney, ST; Vaganay, C; Benaksas, C; Ling, F; Sodaro, G; Meslin, P-A; Bassil, CF; Fenouille, N; Hoj, J; Washart, R; Ang, HX; Cerda-Smith, C; Chaintreuil, P; Jacquel, A; Auberger, P; Forget, A; Itzykson, R; Lu, M; Lin, J; Pierobon, M; Sheng, Z; Li, X; Chilkoti, A; Owzar, K; Rizzieri, DA; Pardee, TS; Benajiba, L; Petricoin, E; Puissant, A; Wood, KC, P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia., Nature Cancer, vol 3 no. 7 (2022), pp. 837-851 [10.1038/s43018-022-00394-x] [abs].